Fundamentals III: Recognizing and Managing AEs and Addressing Adherence and Barriers

Content Format:

Video

Credit Type:

AAPA | ANCC

Credits:

0.75
Fundamentals II: Emerging Role of HER2- and TROP2-Targeted ADCs in NSCLC—What APPs Need to Know

Content Format:

Video

Credit Type:

AAPA | ANCC

Credits:

0.50
Transforming Precision NSCLC Care: Educating and Supporting Patients on HER2-Targeted ADCs

Content Format:

Slideset

Credit Type:

--

Credits:

--
Transforming Precision NSCLC Care: Educating and Supporting Patients on TROP-2–Targeted ADCs

Content Format:

Slideset

Credit Type:

--

Credits:

--
Clinical Landscape of TROP-2–Targeted Therapy in Advanced/Metastatic NSCLC

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.25
Clinical Landscape of TROP-2–Targeted Therapy in Advanced/Metastatic NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Tailored Education on TROP-2‒Targeting ADCs in NSCLC: My Reflections on a Small-Group Collaborative Learning Experience

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
My Thoughts Regarding Use of Adjuvant Osimertinib for Early-Stage EGFR Mutation–Positive NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Expert Think Tank: Lung Cancer Experts Discuss Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Content Format:

Text Module

Credit Type:

ACPE | AMA | ANCC

Credits:

1.25
Expert Think Tank: Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Resources to Improve the Care of Patients With NSCLC and EGFR Mutations

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Checkpoint Inhibition in Stage III NSCLC: Current Practice, Open Questions, and Future Directions

Content Format:

Multimedia

Credit Type:

--

Credits:

--
Current Practice: Checkpoint Inhibitors in Unresectable Stage III NSCLC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
New Immunotherapy Paradigms Earlier in NSCLC: What Comes After Progression?

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
A New Nivolumab Dosing Option for Our Patients With Advanced NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--